825619-03-2

Basic information

• Product Name: 4-(3,4-Dinitrobenzyl)Morpholine
• Synonyms: 4-(3,4-Dinitrobenzyl)Morpholine;Morpholine, 4-[(3,4-dinitrophenyl)Methyl]-
• CAS NO: 825619-03-2
• Molecular Formula: C₁₁H₁₃N₃O₅
• Molecular Weight: 267.23802
• Mol File: 825619-03-2.mol
• Article Data: 12

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 4-(3,4-Dinitrobenzyl)Morpholine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(3,4-Dinitrobenzyl)Morpholine(825619-03-2)
• EPA Substance Registry System: 4-(3,4-Dinitrobenzyl)Morpholine(825619-03-2)

Safety Data

• Hazardous Substances Data: 825619-03-2(Hazardous Substances Data)

Upstream product

• 65003-28-3 (3,4-dinitrophenyl)(morpholin-4-yl)methanone 
• 528-45-0 3,4-dinitrobenzoic acid 
• 24376-18-9 3,4-dinitrobenzoyl chloride 

Downstream Products

• 825619-02-1 4-morpholin-4-ylmethylbenzene-1,2-diamine 
• 825619-29-2 4-((2-(4-nitro-1H-pyrazol-3-yl)-1H-benzo[d]imidazole-5-yl)methyl)morpholine 
• 1254229-30-5 N-{4-[4-chloro-6-({3-[5-(morpholinomethyl)-1H-benzo[d]imidazol-2-yl]-1H-pyrazol-4-yl}amino)pyrimidin-2-ylthio]phenyl}cyclopropanecarboxamide 

Relevant articles and documents

Pyrazole spleen tyrosine kinase inhibitor as well as preparation method and application thereof

The invention discloses a pyrazole spleen tyrosine kinase inhibitor, a preparation method thereof, a pharmaceutical composition containing the same, and application of the pyrazole spleen tyrosine kinase inhibitor and the pharmaceutical composition in the preparation of drugs for treating Syk-mediated diseases including cancers, inflammatory diseases and the like.

As Aurora kinase inhibitor derivatives

The present invention relates to a substituted pyrazole derivative used for inhibiting Aurora kinase and represented by formula (I) or formula (Ia), or stereo isomers, geometric isomers, tautomers, nitrogen oxides, hydrates, solvates, metabolites, esters, pharmaceutically acceptable salts or prodrugs thereof, a medicinal composition containing the above compounds as active ingredients, and a use of the compounds and the medicinal composition in preparation of medicines for protecting, processing, treating or mitigating proliferative diseases of patients.

PYRAZOLYLBENZO[D]IMIDAZOLE DERIVATIVES

A compound represented by the general Formula (I), whereinhydrogen atoms shown as attached to pyrazole and benzimidazole rings are attached to one of nitrogen atoms of the pyrazole or benzimidazole ring, respectively; R1 represents -X-Q-P, wherein X is absent or represents –CH2-, –C(O)-, or –C(O)NH-(CH2)k-, wherein k is 0, 1 or 2; Q is selected from the group consisting of Q1, Q2, Q3, Q4 and Q5; P is absent or represents straight-or branched-chain C1-C3 alkyl, –(CH2)l-NR2R3, or–(CH2)m-C(O)-NR2R3, wherein l and m independently of each other represent 0, 1 or 2, with the proviso that when B in Q1 represents oxygen atom, then P is absent;and R2and R3 independently represent C1 or C2 alkyl, or R2 and R3 together with nitrogen atom to which they are both attached form a 6- membered saturated heterocyclicring, wherein one of carbon atoms can be replaced with oxygen, -NH-or –N(C1-C2)alkyl-; and acid addition salts thereof. The compound can be useful in the treatment of cancer diseases. (I)